ENZ Share Price | Enzo Biochem, Inc. Stock Analysis & Recommendation

Q: How big is Enzo Biochem, Inc.?

Market Cap: As of Jun 18, Enzo Biochem, Inc. has a market capitalization of 28.30 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Enzo Biochem, Inc. reported net sales of 29.09 million and a net profit of -7.60 million.Balance Sheet Snapshot: As of Jul 24, the company's shareholder's funds amounted to 56.11 million, while total assets were reported at 85.76 million.

Q: What does Enzo Biochem, Inc. do?

Overview: Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 7 Million (Quarterly Results - Jan 2025) Most recent Net Profit: -1 Million (Quarterly Results - Jan 2025) Market-cap: USD 28.30 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 1,757.33% Debt Equity: -0.82 Return on Equity: -14.89% Price to Book: 0.65Contact Details: Address: 60 EXECUTIVE BLVD, FARMINGDALE NY: 11735 Tel: 1 516 7555500 Website: http://www.enzo.com/

Q: Is Enzo Biochem, Inc. overvalued or undervalued?

As of 9 June 2022, the valuation grade for Enzo Biochem, Inc. moved from fair to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.67 and an EV to EBITDA ratio of 1.12, which suggests that the market may not be accurately pricing in the challenges faced by the company. Additionally, the negative ROE of -12.03% further underscores the financial difficulties.In comparison to its peers, Enzo Biochem, Inc. has a significantly lower EV to EBITDA ratio than BioAtla, Inc. at -0.2934, highlighting its underperformance within the industry. Furthermore, the company's stock has underperformed against the S&P 500 over multiple periods, with a YTD return of -2.16% compared to the S&P 500's 12.22%, and a staggering 5Y return of -70.39% against the S&P's 96.61%. This trend reinforces the notion that Enzo Biochem, Inc. is currently overvalued.

Q: Is Enzo Biochem, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for Enzo Biochem, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The daily moving averages indicate a mildly bearish trend, while the weekly RSI is bearish. The MACD shows bullish momentum on the weekly but is mildly bullish on the monthly, suggesting mixed signals. The Bollinger Bands are bullish weekly but mildly bearish monthly, and the KST is bullish weekly but bearish monthly. In terms of performance, Enzo Biochem has underperformed significantly against the S&P 500 over the longer term, with a 1-year return of -37.60% compared to the S&P 500's 17.14%, and a 5-year return of -70.39% versus 96.61% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

361.75 k

Shareholding (Jan 2025)

FII

0.79%

Held by 14 FIIs

DII

91.68%

Held by 9 DIIs

Promoter

0.00%

How big is Enzo Biochem, Inc.?

22-Jun-2025

As of Jun 18, Enzo Biochem, Inc. has a market capitalization of 28.30 million, with net sales of 29.09 million and a net profit of -7.60 million over the last four quarters. The company's shareholder's funds are 56.11 million, and total assets are 85.76 million as of Jul 24.

View full answer

What does Enzo Biochem, Inc. do?

22-Jun-2025

Enzo Biochem, Inc. is a micro-cap bioscience company that develops products and services in the Pharmaceuticals & Biotechnology sector. As of January 2025, it reported net sales of $7 million and a net loss of $1 million, with a market cap of $28.30 million.

View full answer

Who are in the management team of Enzo Biochem, Inc.?

22-Jun-2025

As of March 2022, the management team of Enzo Biochem, Inc. includes Dr. Elazar Rabbani as Chairman and CEO, with Mr. Dov Perlysky as Lead Independent Director and independent directors Dr. Rebecca Fischer, Dr. Mary Tagliaferri, and Dr. Ian Walters.

View full answer

Is Enzo Biochem, Inc. overvalued or undervalued?

20-Sep-2025

As of June 9, 2022, Enzo Biochem, Inc. is considered overvalued and risky due to its negative financial metrics, including a Price to Book Value of 0.67, an EV to EBITDA ratio of 1.12, and poor stock performance compared to the S&P 500, with a YTD return of -2.16% and a 5Y return of -70.39%.

View full answer

Is Enzo Biochem, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Enzo Biochem, Inc. is in a mildly bearish trend, indicated by mixed technical signals and significant underperformance against the S&P 500, with a 1-year return of -37.60% compared to the index's 17.14%.

View full answer

Compare Enzo Biochem, Inc. with Similar Stocks

YS Biopharma Co. Ltd.Eliem Therapeutics, Inc.Vaccinex, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 37 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

10,873.16%

Debt Equity

-0.82

Return on Equity

-14.89%

Price to Book

0.84

Revenue and Profits:

Net Sales:

6 Million

(Quarterly Results - Apr 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

24.8%

6 Months

34.9%

1 Year

-37.6%

2 Years

-56.32%

3 Years

-73.73%

4 Years

-78.09%

5 Years

-70.39%

Enzo Biochem, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-19.28%

EBIT Growth (5y)

9.74%

EBIT to Interest (avg)

-12.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.82

Sales to Capital Employed (avg)

1.06

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

36.14%

ROCE (avg)

0.33%

ROE (avg)

1.91%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.67

EV to EBIT

0.94

EV to EBITDA

1.12

EV to Capital Employed

-1.06

EV to Sales

-0.27

PEG Ratio

Dividend Yield

1581.60%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-12.03%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jan 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 9 Schemes (7.53%)

Foreign Institutions

Held by 14 Foreign Institutions (0.79%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is -12.33% vs 17.74% in Jan 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is -100.00% vs 61.29% in Jan 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.40",
          "val2": "7.30",
          "chgp": "-12.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.60",
          "val2": "-0.90",
          "chgp": "-188.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-0.30",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "-1.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-456.70%",
          "val2": "-170.70%",
          "chgp": "-28.60%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jul 2024 is 2.57% vs -4.60% in Jul 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jul 2024 is 60.80% vs -23.15% in Jul 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Jul'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31.90",
          "val2": "31.10",
          "chgp": "2.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.50",
          "val2": "-16.90",
          "chgp": "49.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.70",
          "val2": "-6.00",
          "chgp": "38.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.80",
          "val2": "-25.00",
          "chgp": "60.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-305.00%",
          "val2": "-629.10%",
          "chgp": "32.41%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ

Apr'25

Jan'25

Change(%)

Net Sales

6.40

7.30

-12.33%

Operating Profit (PBDIT) excl Other Income

-2.60

-0.90

-188.89%

Interest

0.00

Exceptional Items

-0.50

-0.30

-66.67%

Consolidate Net Profit

-2.40

-1.20

-100.00%

Operating Profit Margin (Excl OI)

-456.70%

-170.70%

-28.60%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Apr 2025 is -12.33% vs 17.74% in Jan 2025

Consolidated Net Profit

QoQ Growth in quarter ended Apr 2025 is -100.00% vs 61.29% in Jan 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jul'24

Jul'24

Jul'23

Change(%)

Net Sales

31.90

31.10

2.57%

Operating Profit (PBDIT) excl Other Income

-8.50

-16.90

49.70%

Interest

0.20

0.00

Exceptional Items

-3.70

-6.00

38.33%

Consolidate Net Profit

-9.80

-25.00

60.80%

Operating Profit Margin (Excl OI)

-305.00%

-629.10%

32.41%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jul 2024 is 2.57% vs -4.60% in Jul 2023

Consolidated Net Profit

YoY Growth in year ended Jul 2024 is 60.80% vs -23.15% in Jul 2023

All Annual Results

Company CV

About Enzo Biochem, Inc.

Enzo Biochem, Inc.

Pharmaceuticals & Biotechnology

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Company Coordinates

Company Details

60 EXECUTIVE BLVD , FARMINGDALE NY : 11735

Tel: 1 516 7555500

http://www.enzo.com/

Registrar Details

Enzo Biochem, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Enzo Biochem, Inc.?

Watch in Real-Time

What does Enzo Biochem, Inc. do?

Who are in the management team of Enzo Biochem, Inc.?

Is Enzo Biochem, Inc. overvalued or undervalued?

Is Enzo Biochem, Inc. technically bullish or bearish?

Compare Enzo Biochem, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jan 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ

Annual Results Snapshot (Consolidated) - Jul'24

About Enzo Biochem, Inc.

Company Coordinates